Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
3.030
-0.020 (-0.66%)
Nov 16, 2026, 4:00 PM EST - Market closed

Protalix BioTherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
84.6952.7453.465.4947.6438.35
Revenue Growth
36.95%-1.23%-18.47%37.48%24.22%-39.03%
Cost of Revenue
43.2745.8836.739.348.4216.35
Gross Profit
41.426.8616.726.2-0.7922
Selling, General & Admin
12.7711.6812.1914.9611.7112.73
Research & Development
3.450.680.590.780.5229.73
Operating Expenses
16.2112.3612.7815.7412.2342.46
Operating Income
25.21-5.53.9210.46-13.01-20.46
Interest Expense
-0.82-1.19-1.06-3.18-2.53-7.52
Interest & Investment Income
1.461.081.31.291.150.4
EBT Excluding Unusual Items
25.85-5.614.158.57-14.4-27.58
Pretax Income
25.85-5.614.158.57-14.4-27.58
Income Tax Expense
5.311.220.250.53-
Earnings From Continuing Operations
20.55-6.62.938.31-14.93-27.58
Net Income
20.55-6.62.938.31-14.93-27.58
Net Income to Common
20.55-6.62.938.31-14.93-27.58
Net Income Growth
281.00%--64.73%---
Shares Outstanding (Basic)
807973684844
Shares Outstanding (Diluted)
827981824844
Shares Change
-3.09%-3.10%-1.66%70.04%9.81%51.43%
EPS (Basic)
0.26-0.080.040.12-0.31-0.62
EPS (Diluted)
0.25-0.080.040.09-0.31-0.62
EPS Growth
256.60%--57.71%---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
15.07-13.637.39-2.47-25.63-11.74
Free Cash Flow Per Share
0.18-0.170.09-0.03-0.53-0.27
Gross Margin
48.91%13.01%31.27%40.00%-1.65%57.37%
Operating Margin
29.76%-10.43%7.33%15.97%-27.32%-53.36%
Profit Margin
24.27%-12.52%5.49%12.69%-31.33%-71.92%
Free Cash Flow Margin
17.79%-25.84%13.84%-3.77%-53.80%-30.62%
EBITDA
26.83-4.045.2211.65-11.93-19.34
EBITDA Margin
31.67%-7.65%9.78%17.79%-25.04%-50.44%
D&A For EBITDA
1.621.471.31.191.091.12
EBIT
25.21-5.53.9210.46-13.01-20.46
EBIT Margin
29.76%-10.43%7.33%15.97%-27.32%-53.36%
Effective Tax Rate
20.49%-29.42%2.96%--
Revenue as Reported
84.6952.7453.465.4947.6438.35
SEC Filings: 10-K · 10-Q